Golden
Novartis

Novartis

Novartis is a healthcare and pharmaceutical company based in Basel, Switzerland, incorporated in 1996.

Novartis products include oncology medicines, generic and biosimilar medicines and eye car devices. The Innovative Medicine segment of the company is divided into Novartis Oncology and Novartis Pharmaceuticals. Novartis Pharmaceuticals consists of global business franchises in ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic and established medicines. 



Sandoz is a division of Novartis that manufactures, distributes and sells prescription medicines and pharmaceutical active substances that are not patent protected and is franchised into Retail generics, Anti-Infectives and Biopharmaceuticals. 



Alcon is a division of Novartis in the eye car product field in eye care devices and vision care. Alcon’s surgical franchise includes technologies and devices for cataract, retinal, glaucoma and refractive surgery and intraocular lenses to treat cataracts and refractive errors. Alcon’s Vision Care franchise includes contact lenses and contact lens care products. Alcon’s surgical portfolio also includes equipment for performing cataract surgery. 



Novartis, previously called Ciba-Geigy, was one of the few pharmaceutical companies involved in tyrosine kinase inhibitor research when it began a collaboration with oncologist Brian Druker which resulted in discovery of the kinase inhibitor drug Gleevec (also known as Glivec or imatinib). Gleevec was FDA approved in 2001 to treat patients with chronic myelogenous leukemia (CML). Kinases perform phosphorylation, a mechanism that controls the activity of proteins in the cell. CML patients have a mutation causing their tyrosine kinase to be overactive, which signals cell to proliferate at a high rate, resulting in accumulation of immature white blood cells. Based on revenue, Gleevec was one of Novartis’s top ten pharmaceutical products in 2017.



Novartis Oncology drug Kisqali (ribociclib) in Phase III MONALEESA (Mammary Oncology Assessment of LEE011’s (Ribociclib’s) Efficacy and Safety) trials, was reported in December 2018 to demonstrate efficacy and tolerability in combination with endocrine therapy in advanced breast cancer patients with visceral involvement. Kisqali (ribociclib) is a cyclin-dependent kinase inhibitor that inhibits cyclin-dependent kinase 4 and 6 (CDK4/6), proteins that when over active can promote cancer cell division and cancer growth. The drug is an orally available small molecule that acts by blocking phosphorylation of the retinoblastoma protein, which prevents cell-cycle progression. Kisqali is also in the NATALEE study, a Phase III clinical trial with endocrine therapy to treat early breast cancer.



Timeline

April 1, 2019

Novartis agrees to pay $310 million, with the possibility for more later, for some assets of Boston-based IFM Therapeutics.

2010

Novartis bought Alcon's eye surgery and contact lens portfolio in stages through 2010 for $52 billion from Nestle.

People

Name
Role
LinkedIn

Barry X Lynn

Investor



Chris Ilsley

President, Chief Executive Officer



Enrico Vanni

Independent Non-Executive Vice Chairman of the Board



Harry Kirsch

Chief Financial Officer, Member of the Executive Committee



Joerg Reinhardt

Independent Non-Executive Chairman of the Board



Ken Londoner

Advisor



Mike Ryan

Investor



prakash thombre

Investor



Stacia Danielle Sullivan

Founder



Steven Zeppenfeld

Investor



V and K Law

Attorney



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References